Abstract: This study investigates the asynchronous controllability of non-homogeneous Markov switch generalized asynchronous Boolean control networks (NMHGABCNs) and random switching signals in these ...
As OpenAI marks its tenth birthday in December 2025, it can celebrate becoming one of the world’s leading companies, worth perhaps as much as US$1 trillion (£750 billion). But it started as a ...
In risk groups defined by American Urologic Association criteria, recurrences were reported in 8.9% of patients of the low-risk group, 11% of patients in the intermediate-risk group, 22% of those in ...
Recurrences of low-, intermediate-, or high-/very high-risk tumors were again low, intermediate, or high risk in 74%, 62%, and 44% of cases, respectively. Recurrent non-muscle invasive bladder cancer ...
Adding one year of IMFINZI treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone WILMINGTON, Del.-- ...
Non-qualified mortgages cater to those with nontraditional incomes or credit issues. These mortgages may offer lower initial payments but carry higher long-term costs. Non-QM loans don't meet CFPB ...
In Mendelian inheritance patterns, you receive one version of a gene, called an allele, from each parent. These alleles can be dominant or recessive. Non-Mendelian genetics don’t completely follow ...
XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...
Many people dream about leaving the place where they were born or currently live and pursuing a life abroad. Usually, such dreams involve not some random country, but one that seemingly calls to a ...
The FDA approved mitomycin intravesical solution (Zusduri) as a nonsurgical option for recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC). The product won the indication ...
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a leading biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results